Mouse Tnf ASO
Based on 1 Customer Validation
Mouse Tnf ASO is an antisense oligonucleotide (ASO) that targets the expression of mouse TNF-α. Mouse Tnf ASO reduces the tissue levels of various pro-inflammatory cytokines, Th1 cytokines and Th17 cytokines. Mouse Tnf ASO improves the clinical and histopathological severity of experimental colitis, including alleviating weight loss, diarrhea and intestinal protein loss. Mouse Tnf ASO can be delivered to activated colonic macrophages in mice via galactosylated low-molecular-weight chitosan nanocomplexes, with higher delivery efficiency compared to naked ASO. Mouse Tnf ASO can be used in the research of Crohn's disease.
For research use only. We do not sell to patients.
- Purity : 96.43%
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
Mouse Tnf ASO can be delivered into mouse peritoneal macrophages via the gal-LMWC/ASO complex (incubated for 1 h), with higher efficiency than naked Mouse Tnf ASO; through an MGL-mediated mechanism, the uptake level of this complex is enhanced in LPS-prestimulated activated macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
The gal-LMWC/Mouse Tnf ASO complex (5 mg/kg; i.c.; weekly; 5 doses) reduces colonic TNF-α levels by >75% and ameliorates disease symptoms in mice with CD4+CD45RBhi T cell-mediated chronic colitis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (6- to 8-week-old female; TNBS-induced acute colitis)[1]
-
Dosage:0.2 mg/kg, 1.0 mg/kg, 5.0 mg/kg, 20.0 mg/kg
-
Administration:i.c.; single administration
-
Result:Reduced colonic TNF-α protein levels in a dose-dependent manner, with significant decreases at 5.0 and 20.0 mg/kg compared to untreated colitis mice.
Reduced colonic TNF-α mRNA and protein levels by >85% at 5 mg/kg.
Reduced colonic levels of proinflammatory (IL-1β, IL-6), Th1 (IFN-γ, IL-12), and Th17 (IL-17, IL-23) cytokines at 5 mg/kg.
Normalized body weight at 5 mg/kg.
Reduced disease activity index (DAI) scores at 5 mg/kg.
Achieved 100% survival (vs. 40% survival in untreated colitis mice) at 5 mg/kg.
Eliminated macroscopic colonic inflammation at 5 mg/kg.
Reduced colonic myeloperoxidase (MPO) activity to near-normal levels at 5 mg/kg.
Normalized faecal α1-antitrypsin (AAT) levels at 5 mg/kg.
Significantly improved histopathological scores at 5 mg/kg.
-
Animal Model:BALB/c severe combined immunodeficiency (SCID) mice (reconstituted with cells from 6- to 8-week-old female BALB/c mice; CD4+CD45RBhi T cell-mediated chronic colitis)[1]
-
Dosage:5.0 mg/kg
-
Administration:i.c.; weekly; 5 doses
-
Result:Reduced colonic TNF-α mRNA and protein levels by >75%.
Reduced colonic levels of proinflammatory (IL-1β, IL-6), Th1 (IFN-γ, IL-12), and Th17 (IL-17, IL-23) cytokines.
Prevented progressive weight loss.
Reduced disease activity index (DAI) scores.
Eliminated macroscopic colonic inflammation.
Reduced colonic myeloperoxidase (MPO) activity to near-normal levels.
Normalized faecal α1-antitrypsin (AAT) levels.
Significantly improved histopathological scores.
Chemical Information
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Mouse Tnf ASO]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)